Avecho Biotechnology (ASX:AVE) Beneish M-Score : -6.99 (As of May. 05, 2024)

View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -6.99 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Avecho Biotechnology's Beneish M-Score or its related term are showing as below:

ASX:AVE' s Beneish M-Score Range Over the Past 10 Years
Min: -6.99 Med: -4.19 Max: -1.67
Current: -6.99

During the past 13 years, the highest Beneish M-Score of Avecho Biotechnology was -1.67. The lowest was -6.99. And the median was -4.19.

Avecho Biotechnology Beneish M-Score Historical Data

The historical data trend for Avecho Biotechnology's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Beneish M-Score Chart

Avecho Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Get a 7-Day Free Trial

-1.67

-3.12

-2.87

-4.83

-6.99

Avecho Biotechnology Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Beneish M-Score	Get a 7-Day Free Trial															-2.87	-	-4.83	-	-6.99

Competitive Comparison of Avecho Biotechnology's Beneish M-Score

For the Biotechnology subindustry, Avecho Biotechnology's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avecho Biotechnology's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Beneish M-Score falls into.

Avecho Biotechnology Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Avecho Biotechnology for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 3.7517

0.528 * -7.7714

0.404 * -0.017

0.892 * 0.393

0.115 * 0.9112

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 5.2701

4.679 * -0.18978

0.327 * 0.4671

-6.99

This Year (Dec23) TTM:

Last Year (Dec22) TTM:

Total Receivables was A$1.10 Mil.
Revenue was A$0.47 Mil.
Gross Profit was A$-0.04 Mil.
Total Current Assets was A$7.00 Mil.
Total Assets was A$7.32 Mil.
Property, Plant and Equipment(Net PPE) was A$0.32 Mil.
Depreciation, Depletion and Amortization(DDA) was A$0.18 Mil.
Selling, General, & Admin. Expense(SGA) was A$3.08 Mil.
Total Current Liabilities was A$0.84 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.10 Mil.
Net Income was A$-3.44 Mil.
Gross Profit was A$1.13 Mil.
Cash Flow from Operations was A$-3.18 Mil.

Total Receivables was A$0.75 Mil.
Revenue was A$1.21 Mil.
Gross Profit was A$0.87 Mil.
Total Current Assets was A$2.85 Mil.
Total Assets was A$3.35 Mil.
Property, Plant and Equipment(Net PPE) was A$0.47 Mil.
Depreciation, Depletion and Amortization(DDA) was A$0.23 Mil.
Selling, General, & Admin. Expense(SGA) was A$1.49 Mil.
Total Current Liabilities was A$0.75 Mil.
Long-Term Debt & Capital Lease Obligation was A$0.18 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(1.1 / 0.474)	/	(0.746 / 1.206)
	=	2.320675	/	0.618574
	=	3.7517

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0.87 / 1.206)	/	(-0.044 / 0.474)
	=	0.721393	/	-0.092827
	=	-7.7714

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (7.004 + 0.316) / 7.319)	/	(1 - (2.851 + 0.468) / 3.346)
	=	-0.000137	/	0.008069
	=	-0.017

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0.474	/	1.206
	=	0.393

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.23 / (0.23 + 0.468))	/	(0.179 / (0.179 + 0.316))
	=	0.329513	/	0.361616
	=	0.9112

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(3.078 / 0.474)	/	(1.486 / 1.206)
	=	6.493671	/	1.232172
	=	5.2701

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.098 + 0.843) / 7.319)	/	((0.175 + 0.746) / 3.346)
	=	0.128569	/	0.275254
	=	0.4671

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-3.437 - 1.132	-	-3.18)	/	7.319
	=	-0.18978

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Avecho Biotechnology has a M-score of -6.99 suggests that the company is unlikely to be a manipulator.

Avecho Biotechnology Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Avecho Biotechnology (ASX:AVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

OEZ:Germany

Address

Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.avecho.com.au

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology (ASX:AVE) Headlines

No Headlines